Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation - Stoll, P; Bassler, N; Hagemeyer, CE (Arterioscler Thromb Vasc Biol, 2007)
et al.